Related Experiment Video
Updated: Jan 17, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation
Anaïs Schavgoulidze1, Aurore Perrot2, Xavier Leleu3
1Unit for Genomics in Myeloma, University Hospital, University of Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
The International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) genomic model accurately identifies high-risk (HR) multiple myeloma patients, showing significantly shorter progression-free survival (PFS). This validation supports its use in clinical settings for personalized risk assessment.
Area of Science:
- Hematology
- Genomics
- Oncology
Background:
- Prognostic heterogeneity in multiple myeloma is primarily driven by genomic features.
- The International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) proposed a consensus genomic risk model.
- Accurate risk stratification is crucial for managing multiple myeloma (MM).
Purpose of the Study:
- To validate the IMS/IMWG genomic definition of high-risk (HR) multiple myeloma.
- To assess the prognostic impact of the Consensus Genomic Staging (CGS) in a large cohort.
- To evaluate specific genomic criteria associated with poor prognosis.
Main Methods:
- Next-generation sequencing (NGS) panel performed on 6528 newly diagnosed myeloma (NDMM) patients and 1583 first relapse patients (2019-2024).
- Analysis of clinical data for 2695 NDMM patients.
- Comparison of progression-free survival (PFS) between HR and standard-risk (SR) groups.
Main Results:
- 22.4% of NDMM and 36.7% of relapsed patients met HR criteria by CGS.
- HR NDMM patients had a median PFS of 30 months versus 51 months for SR patients (p<0.0001).
- Specific genomic alterations (del(17p), TP53 mutation, biallelic del(1p32), intermediate-risk cytogenetics) significantly reduced PFS.
Conclusions:
- The IMS/IMWG genomic definition effectively identifies HR multiple myeloma.
- The presence of specific genetic aberrations portends a worse prognosis.
- This genomic staging model is validated in a large, contemporary cohort.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
